Deutsche Bank’s Elevation Oncology ELEV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q2
Sell
-185,578
Closed -$48.3K 3639
2025
Q1
$48.3K Sell
185,578
-3,193
-2% -$1.82K ﹤0.01% 3380
2024
Q4
$106K Buy
188,771
+159,751
+550% +$94.3K ﹤0.01% 3276
2024
Q3
$17.4K Hold
29,020
﹤0.01% 3490
2024
Q2
$78.4K Buy
+29,020
New +$109K ﹤0.01% 3191

Other funds holding ELEV

Deutsche Bank's ELEV Position: Q2 2025 in Review

Deutsche Bank sold out of Elevation Oncology (ELEV) in Q2 2025, closing a stake of 185,578 shares — an estimated $48.3K sold.

Deutsche Bank first reported a position in ELEV in Q2 2024 and held it in 4 quarters. The position peaked at $106K in Q4 2024. 65 funds tracked by Wall St. Rank hold ELEV as of Q2 2025.

  • Deutsche Bank reported no remaining Elevation Oncology position as of Q2 2025 after selling out during the quarter.
  • Deutsche Bank sold 185,578 Elevation Oncology shares in Q2 2025, an estimated $48.3K.
  • Deutsche Bank first reported a position in Elevation Oncology in Q2 2024 and held it in 4 quarters.
  • Deutsche Bank's Elevation Oncology position peaked at $106K in Q4 2024.
  • 65 funds tracked by Wall St. Rank held Elevation Oncology as of Q2 2025.

Based on Deutsche Bank's 13F filing for Q2 2025, filed 12 Aug 2025.